ANDA 202076, held by Alkem Laboratories. Acetaminophen; Tramadol Hydrochloride.
As of Nov 21, 2026, ANDA 202076 (Tramadol Hydrochloride and Acetaminophen), held by Alkem Laboratories, was first approved by FDA on Mar 30, 2012, with 9 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 30, 2012 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Tramadol Hydrochloride and Acetaminophen325MG;37.5MG · tablet;oral | Acetaminophen; Tramadol Hydrochloride | Rx |
| Jun 18, 2026 | Supplement 10REMS | Approved | None posted |
| Dec 29, 2025 | Supplement 9Labeling · Standard review | Approved | None posted |
| Dec 15, 2025 | Supplement 7Labeling · Standard review | Approved | None posted |
| Oct 31, 2024 | Supplement 8REMS | Approved | None posted |
| Dec 15, 2023 | Supplement 6Labeling · Standard review | Approved | None posted |
| Dec 13, 2023 | Supplement 5Labeling · Standard review | Approved | None posted |
| Sep 14, 2022 | Supplement 2Labeling · Standard review | Approved | None posted |
| Sep 14, 2022 | Supplement 4Labeling · Standard review | Approved | None posted |
| Sep 18, 2018 | Supplement 3REMS | Approved | None posted |
| Mar 30, 2012 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters